Long-term duration of protection of ancestral-strain monovalent vaccines and effectiveness of the bivalent BA.1 boosters against COVID-19 hospitalisation during a period of BA.5, BQ.1, CH.1.1. and XBB.1.5 circulation in England

Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2023.03.31.23288018

Article Information

doi 
https://doi.org/10.1101/2023.03.31.23288018
History 
  • March 31, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Freja Cordelia Møller Kirsebom, PhD1,
  2. Nick Andrews, PhD1,2,
  3. Julia Stowe, PhD1,
  4. Mary Ramsay, MBBS, FFPH1,2 and
  5. Jamie Lopez Bernal, PhD, MBBS*,1,2,3
  1. 1UK Health Security Agency, London, United Kingdom
  2. 2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom
  3. 3NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, United Kingdom
  1. ↵*Corresponding author: Jamie.LopezBernal2{at}ukhsa.gov.uk
Back to top
Posted March 31, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Long-term duration of protection of ancestral-strain monovalent vaccines and effectiveness of the bivalent BA.1 boosters against COVID-19 hospitalisation during a period of BA.5, BQ.1, CH.1.1. and XBB.1.5 circulation in England
Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2023.03.31.23288018; doi: https://doi.org/10.1101/2023.03.31.23288018
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area